{"meta":{"query_hash":"b011b1033594","filters":{"venue":"Research in Oncology"},"cohort_total":1,"direct_labels_cover":0,"predictions_cover":1,"exported":1,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b011b1033594","api":"https://metacan.xera.ac/api/v1/cohort?venue=Research+in+Oncology"},"results":[{"id":"W2745096287","doi":"10.21608/resoncol.2013.451","title":"Zoledronic Acid in Breast Cancer Patients with Bone Metastasis","year":2013,"lang":"en","type":"article","venue":"Research in Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Zoledronic acid; Breast cancer; Bone metastasis; Oncology; Medicine; Internal medicine; Metastasis; Cancer; Cancer research","score_opus":0.06744678356782459,"score_gpt":0.44617423405760853,"score_spread":0.37872745048978396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745096287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884311,0.009713252,0.000060191513,0.0002751243,0.00002746669,0.00003976398,0.00021794862,0.000007905347,0.0012271958],"genre_scores_gemma":[0.9974751,0.0018469036,0.00007922012,0.00017936698,0.000037761147,0.000016845477,0.00019204585,7.317648e-7,0.00017202011],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9998797,0.000026753098,0.000014629795,0.000016757507,0.00003156632,0.000030476054],"domain_scores_gemma":[0.99983346,0.00004210557,0.00007153129,0.00000414863,0.000014575115,0.00003416763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017504835,0.0001133424,0.00043117668,0.00023957173,0.0002420627,0.00026487827,0.00011495759,0.00025788666,0.0011185613],"category_scores_gemma":[0.0007422999,0.00008510967,0.00027588315,0.0005736784,0.000085443244,0.00011623458,0.0001224962,0.00019359897,0.00012978581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034603805,0.00021576237,0.95966035,0.00030757193,0.00016627902,0.0022822302,0.00011217295,0.00022104234,0.00211118,0.000052641437,0.0012244491,0.030185886],"study_design_scores_gemma":[0.00067038205,0.002497815,0.98230827,0.000090326925,0.00035037583,0.008984947,0.00016936153,0.0005759267,0.0006219217,0.00011898268,0.0036012742,0.000010430933],"about_ca_topic_score_codex":0.0015315323,"about_ca_topic_score_gemma":0.002830307,"teacher_disagreement_score":0.0015315323,"about_ca_system_score_codex":0.00028466366,"about_ca_system_score_gemma":0.00033256496,"threshold_uncertainty_score":0.0037419796},"labels":[],"label_agreement":null}]}